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The second heart field (SHF), progenitor cells that are initially seques-
tered outside the heart, migrates into the heart and gives rise to
endocardium, myocardium, and smooth muscle. Because of its distinct
developmental history, the SHF is likely subjected to different signals
from that of the first heart field. Previous experiments revealed that
canonical Wnt signaling negatively regulated first heart field speci-
fication. We inactivated the obligate canonical Wnt effector-catenin
using a -catenin conditional null allele and the Mef2c AHF cre driver
that directs cre activity specifically in SHF. We also expressed a
stabilized form of -catenin to model continuous Wnt signaling in
SHF. Our data indicate that Wnt signaling acts in a positive fashion to
promote right ventricular and interventricular myocardial expansion.
Cyclin D2 and Tgf2 expression was drastically reduced in -catenin
loss-of-function mutants, indicating that Wnt signaling is required for
patterning and expansion of SHF derivatives. Our findings reveal that
Wnt signaling plays a major positive role in promoting growth and
diversification of SHF precursors into right ventricular and interven-
tricular myocardium.
conditional genetics  cardiac progenitor  mouse  development
Previous work using retrospective clonal analysis in mouseembryos indicated that the heart developed from two pop-
ulations of cardiac progenitors. Cells within the first heart field
(FHF) uniquely contribute to the left ventricular myocardium
whereas the second heart field (SHF) contributes to outflow
tract (OFT) and right ventricular (RV) myocardium, endocar-
dium, and smooth muscle of the great vessels (1–5). Each
progenitor population expresses distinct and overlapping mo-
lecular markers: the Hand1 and Tbx5 transcriptional regulators
mark the FHF whereas Fgf10 and the Lim-homeobox gene Isl1
mark the SHF. Recent work indicates that Isl1 may also be
transiently expressed in the FHF (6). TheNkx2.5 homeobox gene
is expressed in both lineages (7).
Genetic experiments performed in mice revealed that Isl1 had
a critical function in SHF. Importantly, although Isl1 is expressed
in SHF cardiac progenitors, Isl1 expression is extinguished in the
majority of the heart with the exception of a subpopulation of
cardiac progenitors that persist in the adult (4, 8). Other
experiments, revealing that the Mef2c transcription factor is a
direct Isl1 target, uncovered a SHF transcriptional hierarchy (9).
The SHF has been proposed to be a source of adult progenitor
cells. Recent work has led to the proposal that Isl1-expressing
progenitors provide a source of resident progenitor cells, or
cardioblasts, that have the capability to differentiate into mature
cardiomyocytes (8). Experiments performed in embryonic stem
cells revealed that the Isl1-positive lineage gives rise to endo-
thelial cells, smoothmuscle cells, and cardiomyocytes, suggesting
the intriguing possibility, as yet unproven, that the adult heart
may harbor a stem cell niche (10–13).
Despite the importance of the SHF in cardiac development, a
clear picture of the regulatory pathways controlling SHF devel-
opment and diversification is lacking. An enhancer trap into the
Fgf10 locus provided early evidence for the existence of the SHF
in mice and indicates, along with conditional loss-of-function
experiments, the involvement of Fgf signaling in SHF formation
(14–16). Likewise, Bmp signaling has been implicated in SHF
development based on data from chick embryos and mouse
conditional deletion studies (6, 17, 18).
TheWnt family of secreted glycoproteins has been implicated in
numerous events in development and disease (19). -Catenin, an
obligate effector of the canonical Wnt pathway, is stabilized in the
presence ofWnt signaling and enters the nucleus, where it interacts
with TCF factors, such as Lef1, to regulate gene expression. In the
absence of Wnt signaling, -catenin is targeted for destruction by
the APC, Axin, Gsk3b complex that phosphorylates -catenin and
directs it to a destruction pathway (19). -Catenin also complexes
with the cytoplasmic domain of E-cadherin where it plays a fun-
damental role in promoting cell adhesion.
Previous findings indicated that Wnt signaling from the neural
tube inhibits FHF specification (20–22). It is unclear whether Wnt
signaling influences the SHF in a similar fashion as the FHF.
Because Wnt signaling is known to promote development of trunk
skeletal muscle, it was conceivable that Wnt signaling could pro-
mote SHF development from splanchnic mesoderm (23).
In this work we investigated -catenin-dependent Wnt signal-
ing in the SHF. We inactivated -catenin in the SHF using the
Mef2c AHF cre (hereafter referred to asMef2ccre) that directs cre
activity specifically in SHF (9, 24) (kindly provided by B. Black
and M. Verzi, University of California, San Francisco, CA). Our
findings indicate that -catenin function is required for expan-
sion of the RV and interventricular septum, as well as patterning
of OFT cushions.
Results
Manipulation of -Catenin Function in Second Cardiac Lineage. To
investigate Wnt signaling in second cardiac lineage, we gener-
ated mouse embryos with loss and gain of -catenin function
specifically in SHF. The Mef2ccre transgene directs cre activity
specifically in SHF [supporting information (SI) Fig. 7A]. Lin-
eage tracing with Mef2ccre and Rosa26Reporter (R26R) allele
labels cells in the dorsal medial aspect of the crescent at 7.5 days
postcoitum (dpc) (SI Fig. 7 B and C). As cardiac development
progresses, theMef2ccre lineage contributes to OFTmyocardium,
pharyngeal mesenchyme, and OFT endocardium (SI Fig. 7D–I).
Activity of the Mef2ccre transgene is excluded from the pharyn-
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geal endoderm, making this an ideal cre driver to investigate
gene function in the specified SHF (SI Fig. 7 E, G, and I) (24).
The -cateninflox allele contains LoxP sites flanking exons 2–6
and has been shown to be a conditional null allele (SI Fig. 7J)
(25). We used theMef2ccre transgenic line to delete -catenin, an
obligatory downstream canonical Wnt effector. -Catenin dele-
tion in Mef2ccre-expressing cells would render SHF resistant to
Wnt signaling. As a complementary experiment, we expressed a
stabilized form of -catenin in the Mef2ccre-expressing SHF to
model gain of function or continuous Wnt signaling (26). The
-cateninex3flox allele is a mutant -catenin allele containing a
LoxP-flanked exon 3 that encodes residues that are required for
negative regulation of -catenin (SI Fig. 7K) (26). When -
catenin exon 3 is removed by cre-mediated recombination, the
resulting mutant allele encodes a stabilized form of -catenin
that mimics sustained Wnt signaling.
Efficient -Catenin Deletion by Mef2ccre. To remove -catenin
function from specified SHF, we crossed the -cateninflox allele
to the Mef2ccre transgenic line (24, 25). We used immunofluo-
rescent microscopy to determine the efficiency of -catenin
deletion in SHF. At 9.5 dpc we detected -catenin in the
pharyngeal mesenchyme and OFT myocardium of control em-
bryos (Fig. 1 A and B). We noted membrane-localized -catenin
in epithelial tissues such as branchial arch ectoderm and pha-
ryngeal endoderm. Moreover, we detected nuclear-localized
-catenin, a hallmark of active Wnt signaling, in the pharyngeal
mesenchyme and OFT myocardium (Fig. 1B). In Mef2ccre;
-cateninflox conditional mutants, we found a strong reduction in
-catenin immunostaining in the SHF-derivedOFTmyocardium
and pharyngeal mesenchyme (Fig. 1 C and D), indicating that
Mef2ccre efficiently deleted -catenin in SHF.
Mef2ccre; -Cateninflox Conditional Mutants Have a Reduced Right
Ventricle. Examination of Mef2ccre; -catenin conditional null
mutant embryos at multiple stages revealed that all -catenin
loss-of-function mutants had defective OFT and RV develop-
ment. In particular, the RV was drastically reduced when
compared with control embryos (Fig. 2 A and A). Histologic
analysis also indicated that, at 12.5 dpc, -catenin conditional
null mutants had defective separation of the distal OFT (Fig. 2
B and B). More proximal sections revealed that, in the proximal
OFT, the pulmonary trunk and aorta were separated (Fig. 2 C
and C). Sections through the RV indicated that the RV was
reduced in size with a thin myocardium (Fig. 2 D and D). The
OFT length was also reduced in -catenin conditional null
mutants when compared with control (Fig. 2 E and E). To-
gether, the phenotypes detected in -catenin conditional null
mutants indicated a major deficiency in SHF derivatives.
Deficiency of SHF Derivatives in -Catenin Conditional Mutants. We
studied SHF markers to investigate the -catenin conditional null
mutant phenotype in more depth. Expression of Isl1 was intact in
the -catenin conditional null mutants as would be expected
because Mef2c is a downstream target of Isl1 in SHF (9) (Fig. 3 A
and A). Moreover, expression of cardiac neural crest (CNC)
markers indicated that CNC was specified correctly in -catenin
mutants (Fig. 3 B, B, C, and C). Lineage tracing with R26R, to
follow the developmental progression of the Mef2ccre lineage,
indicated that in -catenin mutant embryos the SHF was severely
defective (Fig. 3 E, E, F, and F). Whole-mount LacZ staining
showed the reduced size of the RV and defective distal OFT
A B
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Fig. 1. Mef2ccre induced -catenin deletion in SHF. Immunofluorescent
staining of -catenin in 9.5 dpc sagittal sections of control (A and B) and
Mef2ccre; -cateninflox mutant (C and D) embryos revealing membrane-
localized -catenin staining in ectoderm and endoderm as well as nuclear
-catenin in OFT myocardium, posterior pericardial mesothelium, and pha-
ryngeal mesenchyme (denoted by white arrowheads in B). In the Mef2ccre;
-cateninflox mutant there is reduced -catenin expression in pharyngeal
mesenchyme and OFT myocardium, but not endocardium, due to mosaic
activity ofMef2ccre in OFT endocardium (decreased-catenin denoted by blue
arrows). A, atrium; BA, branchial arch; EC, endocardium; PE, pharyngeal
endoderm.
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Fig. 2. Phenotype of Mef2ccre; -catenin mutant embryos. Shown are morphology and histology of 10.5–12.5 dpc -catenin loss-of-function mutant hearts
showing severe RV hypoplasia (*) (A) compared with control littermate (A). Transverse section of 12.5 dpc (B, B, C, C, D, and D) and sagittal section of 10.5
dpc (E and E) control and -catenin loss-of-function mutant hearts reveal severe cardiac abnormalities: OFT septation defect in the distal OFT (B and B,
arrowheads) but not in more proximal OFT (C and C), and hypoplasia of RV myocardium (D and D, arrow) and short OFT (E and E, double-headed arrows).
Endocardium is denoted by arrowheads. PT, pulmonary trunk; LV, left ventricle; RV, right ventricle; RA, right atrium; LA, left atrium; Es, esophagus, Tr, Trachea,
Br, bronchi.
9320  www.pnas.orgcgidoi10.1073pnas.0701212104 Ai et al.
separation in -cateninmutant embryos (Fig. 3D andD). Sections
revealed a major deficiency of SHF-derived cells in the RV and
interventricular septum (Fig. 3E,E, F, and F). Dysmorphology of
theOFT cushions was also evident in these sections, suggesting that
a -catenin target is a signaling molecule that functions to pattern
ingressing CNC (Fig. 3 E and E). These findings indicate that, in
contrast to its inhibitory influence on the FHF, Wnt signaling
promotes SHF development.
Defective Expression of Myocardial Markers in -Catenin Conditional
Mutants. To address the genetic pathways regulated by Wnt
signaling in SHF, we examined molecular markers of the SHF
and its derivatives. Cyclin D2, a direct target of -catenin-
dependent Wnt signaling, is expressed in pharyngeal mesen-
chyme and in proximal OFT (27). At both 9.5 dpc and 10.5 dpc,
CyclinD2 was absent in the OFT of -catenin mutants validating
loss of competence to respond to Wnt signaling (Fig. 4 A–D). To
determine whether there was a defect in regionalization of the
-catenin mutant OFT, we examined Tgf2 expression that
marks the most distal OFT myocardium. In -catenin mutants,
Tgf2 was severely diminished, indicating that both distal and
proximal OFT myocardium was defective in -catenin mutants
(Fig. 4 E and F). In contrast, expression of Smarcd3, which
encodes a component of the BAF chromatin remodeling com-
plex and a proposedWnt target in the heart, was unchanged (Fig.
4 G and H) (28). Absence of Cyclin D2 expression in -catenin
mutants suggested a defect in proliferation. Expression of
phospho-Histone H3, which marks mitotic cells, was greatly
reduced in -cateninmutants, supporting the idea that canonical
Wnt signaling was required for normal proliferation of OFT and
RV myocardium (Fig. 4 I and J). Taken together, these data
indicate that patterning and expansion of SHF-derived myocar-
dium are severely disrupted in -catenin mutant embryos.
Expression of Stabilized -Catenin Causes Defective Right Ventricle
Development.Weused the-cateninex3flox allele to express stabilized
-catenin in the SHF. This gain-of-function experiment models the
effect of continuous, deregulatedWnt signaling on SHF progenitor
cells. The RV was severely reduced in Mef2ccre; -cateninex3flox
embryos (Fig. 5 A and B). Sectioning indicated that OFT and RV
myocardium was thickened and hypercellular in the Mef2ccre;
-cateninex3flox embryos (Fig. 5 C–F). We also noted that a region
of the left ventricular myocardium was thickened (Fig. 5F, arrow-
head). This likely reflects the contribution of the SHF to the left
ventricular region near the interventricular septum (24). Taken
together, these data indicate that both loss and gain of -catenin
function resulted in defective RV development. It is notable that in
other systems, such as tooth development, excess and reducedWnt
signaling results in a similar tooth-loss phenotype (29, 30).
Disrupted Bmp4 Expression in -Catenin Conditional Mutants. We
compared expression of SHF markers in the -catenin loss- and
gain-of-function embryos. Nkx2.5, which plays an early role in
SHF specification, was expressed in the pharyngeal mesenchyme
and SHF derivatives of both loss- and gain-of-function embryos,
supporting the idea that SHF is correctly specified in Mef2ccre;
-catenin floxmutant embryos (Fig. 6A–C) (6). In contrast, Bmp4
was greatly reduced in the pharyngeal mesenchyme and OFT
myocardium of -catenin loss-of-function embryos (Fig. 6 D and
E). -Catenin gain-of-function embryos expressed Bmp4 in both
pharyngeal mesenchyme and OFTmyocardium (Fig. 6D and F).
Fgf10 expression in pharyngeal mesenchyme was unchanged in
-catenin loss-of-function embryos and had a considerably re-
duced expression domain in -catenin gain-of-function embryos
(Fig. 6 G–I). We also noted low levels of Fgf10 in the OFT that
was diminished in both -catenin loss- and gain-of-function
embryos. MLC2a, a marker of differentiated myocardium, was
reduced in -catenin gain-of-function embryos, indicating a
differentiation defect. In -catenin loss-of-function mutants,
expression ofMLC2awas similar to control embryos (Fig. 6 J–L).
Discussion
Previous experiments revealed an inhibitory role for canonical
Wnt signaling in FHF precursors (22, 31, 32). In contrast,
canonical Wnt signaling has been shown to promote trunk
skeletal muscle development (33, 34). Our data indicate that
canonical Wnt signals promote development of SHF progenitors
into RV and interventricular myocardium. These findings un-
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Fig. 3. Marker analysis of SHF and CNC and Mef2ccre lineage tracing in Mef2ccre; -cateninflox mutants. In situ hybridizations of Isl1 (A and A), Sox10 (B and
B), and Ap2 (C and C) at 9.5 dpc indicated that SHF and CNC were correctly specified in Mef2ccre; -catenin conditional mutant embryos (yellow arrowheads
denote hybridization signal). Mef2ccre lineage tracing (D and D) and transverse section (E, E, F, and F) in wild type and -catenin mutant revealed a severe
deficiency in the Mef2c lineage in Mef2ccre; -catenin conditional mutant embryos. LV, left ventricle; RV, right ventricle; RA, right atrium; LA, left atrium; AO,
aorta; PT, pulmonary trunk; Ba, branchial arch.
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cover a striking difference between the two cardiac progenitor
populations in the use of Wnt signaling to promote or repress
formation of the mature cardiomyocyte phenotype.
Wnt Signaling Is Critical for Development of the Right Ventricle. We
deleted -catenin using the Mef2ccre driver that is active after Isl1
expression has been initiated in SHF. Therefore, we removed
competence to respond to Wnt signaling after SHF specification.
Although in situ data indicate that patterning of the proximal and
distal OFT is disrupted, the most severely affected cells are the RV
and interventricular progenitors. Our findings are consistent with
the previous observation that RV and interventricular myocardium
derives from SHF (35). One explanation for the stronger RV and
interventricular myocardial phenotype may be that the OFT myo-
cardial lineage is specified or expands earlier than RV and inter-
ventricular septum. This notion is analogous to data from ES cells
in which Nkx2.5 GFP-expressing cells are more restricted than
Brachury GFP-expressing cells in their potential for lineage diver-
sification or expansion (36). It is conceivable that other signals, such
as Bmp signaling, have a role in specification or expansion of OFT
myocardium and endocardial lineages (see below).
Previous work revealed that noncanonical Wnt signaling plays a
critical role in cardiac development. The noncanonical Wnt signal-
ing pathway is -catenin-independent but utilizes Dsh and Rho
(37). Wnt11 has been shown to regulate cardiac development
through a noncanonical pathway inXenopus and zebrafish embryos
(38, 39). Moreover, Loop-tail (Lp), a naturally occurring mouse
mutant that was initially identified based on severe defects in neural
tube closure, has cardiac OFT defects. The gene mutated in Lp is
Vangl2, a homolog of the Drosophila planar cell polarity gene
Strabismus. Recent work has shown that Vangl2 functions in the
OFT myocardium to regulate OFT septation (40).
Our work provides insight into the role of Wnt signaling in
SHF by showing that the canonical Wnt pathway promotes SHF
development. It is notable that Wnt11, highly expressed in OFT
myocardium, has also been implicated in canonicalWnt signaling
in Xenopus embryos (41). Therefore, it is conceivable thatWnt11
activates the canonical pathway in SHF derivatives, but further
experiments will be required to investigate this.
ββ
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Fig. 4. Marker analysis of OFT myocardium in Mef2ccre; -cateninflox mutants. In situ hybridization with Cyclin D2 (A–D), Tgf2 (E and F), and Smarcd3 (G and
H) in control and Mef2ccre; -cateninflox mutants at 9.5 dpc. Pharyngeal mesenchyme is denoted by yellow arrowheads, and OFT is denoted by black arrowheads.
(I and J) Sagittal sections of phospho-histone H3 immunostaining at 9.5 dpc. Arrowheads denote PH3 signal. lv, left ventricle; ba, brachial arch.
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Fig. 5. Phenotype ofMef2ccre;-cateninEx3flox mutant embryos. Morphology
and serial, transverse sections of 9.5 dpc wild-type (A, C, and E) and Mef2ccre;
-cateninEx3flox mutant embryos (B, D, and F) showing short but more dense
and hypercellular OFT myocardium (denoted by black arrows). nt, neural tube;
ba, branchial arch; LV, left ventricle; ph, pharynx.
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The Intersection of Wnt and Bmp Signaling in SHF and SHF Derivatives.
Bmp signaling has been implicated in the addition of SHF progen-
itors to theOFT and has been considered to be a prodifferentiation
pathway in the SHF. For example, Noggin-coated bead implanta-
tion in SHF explants resulted in increased cell proliferation (18).
Conditional genetic experiments inmice support this interpretation
because Mespcre; Smad1f/f mutants, which delete the Bmp effector
Smad1 widely in mesoderm, have elongated OFTs and elevated
proliferation in SHF but not OFT myocardium (6). In addition,
Nkx2.5cre; Bmp4 flox mutants, which have a broad Bmp4 deletion in
SHF, SHF derivatives, and pharyngeal endoderm, show elevated
proliferation in OFT myocardium (17). In contrast to what might
have been predicted, our data indicate that -catenin loss-of-
function embryos with reduced Bmp4 in pharyngeal mesenchyme
and OFT myocardium have less myocardial proliferation.
We also noted that -catenin loss-of-function embryos had
defective patterning of OFT cushions that are partly derived from
CNC. Because our strategy to inhibit Wnt signaling competence
was limited to the SHF, the defect in CNC patterning indicates that
there is a nonautonomous signal acting downstream of -catenin.
Published data reveal that inactivation of Bmp ligands in SHF, and
type I Bmp receptors in CNC resulted in defective cardiac cushion
development, supporting the notion that Bmp signals from SHF
regulate development of the CNC (17, 42–44).
Previous work has uncovered dosage-dependent functions for
Bmp signaling in mandibular development (45). This notion of
distinct, dosage-dependent functions for Bmp signaling likely also
applies to the SHF and SHF derivatives as suggested by the OFT
phenotype of the Bmpr2 hypomorph previously reported by Lyons
and colleagues (46). Moreover, we have recently found that Bmp2
and Bmp4 function cooperatively in the SHF to regulate distinct
events in the forming OFT (L. Ma and J.F.M., unpublished
observations). Together our findings suggest that residual Bmp4
expression in -catenin loss-of-function embryos is sufficient to
maintain the antiproliferative Bmp function but fails to support
CNC patterning (Fig. 6M). The -catenin loss-of-function embryos
had reduced Fgf10 expression in the OFT myocardium, which also
likely contributes to diminished proliferation in the mutant OFT.
Fgf signaling has been shown to be an important signal that
promotes expansion of SHF derivatives (15, 16).
Stabilized -Catenin Disrupts SHF Development. The phenotype we
observed in -catenin gain-of-function embryos, a short hyper-
cellular OFT, likely represents a disruption of the normal
balance between progenitor cell expansion and precisely timed
differentiation. In support of this idea, we observed reduced
Fgf10 expression in the SHF of -catenin gain-of-function em-
bryos. As noted above, Fgf signaling in SHF is generally con-
sidered to promote proliferation; reduced Fgf signaling would
likely result in a shorter OFT (15, 16, 18). In contrast, once SHF
cells have moved into the OFT canonical Wnt signaling has a
more direct role in promoting cellular proliferation and myo-
cardial expansion (Fig. 6M). This would account for the myo-
cardial hypercellularity and reduced MLC2a expression in the
-catenin gain-of-function embryos.
Moreover, these data suggest that elevated Wnt signaling has
a negative influence on expansion of undifferentiated SHF in
pharyngeal mesenchyme. These data support previous sugges-
tions that Wnt signaling may have a role in delaying SHF from
contributing to myocardium until looping stages.
Implications for Signaling in Cardiac Progenitor Cells and Right
Ventricular Development. Our findings show that Wnt signaling
plays a critical, positive role in promoting SHF expansion and
diversification. This observation may have therapeutic implica-
tions because a number of laboratories have identified multipo-
tent cardiac progenitor cells (10–12). An important goal would
be to identify the signaling molecules that promote progenitor
cell expansion. Our data indicate that Wnt signaling is an
excellent candidate to promote growth of cardiac progenitors.
Moreover, our findings indicate that Bmp signaling likely has a
downstream function in this pathway (Fig. 6M). This is partic-
ularly intriguing considering the proposed role for Bmp4 in
self-renewal in embryonic stem cells (47).
Materials and Methods
Whole-Mount in Situ Hybridization.Whole-mount in situ hybridiza-
tion was performed as previously described (48). Details about
the in situ probes will be provided upon request. For all
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Fig. 6. Marker analysis in -catenin loss-of-function and gain-of-function
mutant embryos. (A–L) Analysis of markers for SHF and differentiated myo-
cardium in 9.5-dpc embryos. Genotypes and markers are labeled. Pharyngeal
mesenchyme is denoted by yellow arrowheads, and OFT is denoted by black
arrowheads. OFT is outlined by a dotted line in G–I for clarity. (M) Model
depicting the proposed role of canonical Wnt signaling in SHF. Based on loss-
and gain-of-function experiments, canonical Wnt signaling promotes Bmp4
expression while concurrently acting to restrict Fgf10 in the SHF. The dotted
line for Fgf10 repression indicates that this may be a minor function for Wnt
signaling in the SHF because the data supporting this inhibitory function were
observed only in the gain-of-function experiment. In the SHF-derived myo-
cardium of the OFT, RV, and interventricular septum (IVS), canonical Wnt
signaling regulates Bmp4 and promotes cell proliferation through regulation
of Cyclin D. ba, branchial arch; RV, right ventricle; lv and LV, left ventricle; oc,
otic capsule.
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experiments, at least three embryos were used for each probe at
each time point examined.
LacZ Staining and Histology. For histology, embryos were fixed
overnight in Bouin’s fixative or buffered formalin, dehydrated
through graded ethanol, and embedded in paraffin. Sections
were cut at 7–10 m and stained with H&E. Staining for
-galactosidase (LacZ) was as previously described (48).
Mouse Alleles and Transgenes. TheMef2cAHFcre transgenic line has
been previously described (9, 24). Briefly, the Mef2cAHFcre trans-
genic line uses a 3,970-bp enhancer and promoter element from the
Mef2c gene to direct cre recombinase expression in the SHF. The
-catenin conditional null allele has been described previously (25).
For genotyping, DNA was extracted from yolk sacs or tails of
embryos and adult mice, respectively. PCR was used to determine
the genotype. The primers used were described (25). The -catenin
dominant stable allele has also been described previously (26). The
genotyping primers used were 5-AGCTGCTGTGACAC-
CGCT-3 and 5-GCTACTTGCTCTTGCGTGAA-3. The ampli-
fied product for the mutant allele is 700 bp.
Immunohistochemical Staining. Embryos were collected at desired
stages and fixed in 4% paraformaldehyde for 30 min. Tissues
were washed with PBS twice, dehydrated, and embedded in
paraffin as previously described. Immunofluorescence staining
was carried out on 5-m sections as previously described (49).
Briefly, sections were first blocked with 2% BSA in PBST and
incubated with anti--catenin (1:600; Cell Signaling Technology,
Beverly, MA) for 1 h. After three 10-min washings, Alexa Fluor
488-conjugated secondary anti-rabbit IgG (1:800; Molecular
Probes, Eugene, OR) was added and incubated for 1 h. The
secondary antibody was then washed off, and the sections were
counterstained with propidium iodide and mounted with Aqua-
Mount (Lerner Laboratories, Pittsburgh, PA). Images were
captured by an Olympus FluoView confocal microscopy system.
For phospho-histone H3 (PH3) immunostaining antigen re-
trieval was performed by boiling slides in 10 mM sodium citrate
(pH 6.0, 5 min) followed by treatment with 3% H2O2 to quench
endogenous peroxidase. Specimens were blocked in 2% normal
goat serum (NGS) for 1 h at room temperature and incubated
overnight at 4°C with the anti-phospho-Histone H3 (Ser-10)
antibody (Upstate Biotechnology, Lake Placid, NY) diluted
1:200 in 2% NGS, followed by incubation in biotinylated anti-
rabbit secondary antibody (Vector Laboratories, Burlingame,
CA) diluted 1:200 in 2% NGS for 1 h at room temperature.
Sections were processed by immunoperoxidase labeling using
the Vectastain ABC Kit (Vector Laboratories) and visualized
with a DAB kit (Vector Laboratories).
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